Effect of vitamin D supplementation on various parameters in non-alcoholic fatty liver disease patients.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of fatty liver & elevated liver enzymes, published as a randomized controlled trial.

The purpose is to investigate the effect of oral vitamin D supplementation on various parameters in NAFLD patients.

Why It Was Studied

There are still no FDA approved drugs for NAFLD so far.

Vitamin D may be a good therapeutic option for NAFLD patients due to its insulin sensitizing and anti-inflammatory properties.

Who Took Part

The study group was 109 patients.

By PubMed's age tags, the people studied were adults, both men and women.

Anthropometric, chemical, metabolic and inflammatory parameters were assessed pre and post treatment by using SPSS 16.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Adiponectin, Body Mass Index, C-Reactive Protein, Insulin Resistance, Lipids, Liver and Non-alcoholic Fatty Liver Disease.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 109 patients in people with fatty liver & elevated liver enzymes.

The publication is from 2019 (Pakistan journal of pharmaceutical sciences), a journal based in Pakistan.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Fatty liver & elevated liver enzymes research.